Sorrento Therapeutics, Inc. (SRNE) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 0.31: the stock has moved about 69% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerSorrento Therapeutics, Inc. (SRNE) trades at $0.0008. Sorrento Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for various diseases, including cancer and autoimmune disorders. Sector: Healthcare.
Price as of · Last analyzed: Jun 14, 2026Analyst Coverage for SRNE: SRNE does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Sorrento Therapeutics, Inc. (SRNE) Healthcare & Pipeline Overview
Sorrento Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops targeted therapies for cancer and other serious diseases, utilizing its proprietary G-MAB antibody library and advanced drug delivery technologies to address unmet medical needs.
What Is the Investment Thesis for SRNE?
Sorrento Therapeutics, Inc. is positioned for growth through its diverse pipeline of innovative therapies targeting significant medical needs. Key value drivers include the ongoing development of anti-CD38 CAR-T therapy, which addresses a substantial market in multiple myeloma, and the Phase III trials for SEMDEXA, potentially tapping into the growing market for pain management solutions. The company's unique drug delivery technology, Sofusa, presents a competitive advantage in enhancing drug efficacy, particularly in oncology. With a gross margin of 46.8%, Sorrento's financial metrics indicate operational efficiency, although the company currently operates at a profit margin of -911.6%. As the biopharmaceutical industry continues to expand, driven by increasing demand for novel therapies, Sorrento's strategic collaborations and innovative product offerings position it favorably for future growth. Investors should monitor the progress of clinical trials and regulatory approvals as potential catalysts for stock performance.
Based on FMP financials and quantitative analysis
SRNE Key Highlights
Market Cap: $0.00B, indicating a current lack of market valuation due to trading on OTC markets.
- Profit Margin: -911.6%, reflecting significant operational challenges during clinical development phases.
- Gross Margin: 46.8%, demonstrating the potential for profitability upon successful product commercialization.
- Beta: 0.31, indicating lower volatility compared to the broader market, suggesting stability in investor sentiment.
- No Dividend Yield, as the company reinvests earnings into research and development.
Who Are SRNE's Competitors?
SRNE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals, Inc. | $735.20 | +0.05% | $75.7B | 94 5-pillar |
| AMGN Amgen Inc. | $403.04 | -1.04% | $218B | 85 5-pillar |
| GILD Gilead Sciences, Inc. | $144.74 | -1.87% | $179B | 64 5-pillar |
| ICCC ImmuCell Corporation | $9.75 | +1.56% | $88.2M | 79 5-pillar |
| RLYB Rallybio Corporation | $17.08 | +1.91% | $90.6M | 83 5-pillar |
| ALPX Alopexx, Inc. | $9.96 | 0.00% | $119M | 65 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.49 | +0.22% | $184M | 76 5-pillar |
| ANTX AN2 Therapeutics, Inc. | $5.71 | +1.60% | $206M | 67 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SRNE's Key Strengths?
Innovative proprietary technologies like G-MAB and Sofusa.
- Diverse pipeline targeting multiple therapeutic areas.
- Strong collaborations with leading research institutions.
What Are SRNE's Weaknesses?
High operational costs leading to negative profit margins.
- Dependence on successful clinical trial outcomes for revenue generation.
- Limited market capitalization due to OTC trading.
What Are the Key Risks for SRNE?
Financial-distress signal — its Altman Z-Score of -10.88 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Regulatory challenges in obtaining approvals for new therapies.
- High operational costs leading to negative profit margins.
- Intense competition from established biotechnology companies.
What Threats Does SRNE Face?
- Intense competition from established biotechnology firms.
- Regulatory hurdles in obtaining approvals for new therapies.
- Market volatility affecting investor confidence in OTC stocks.
What Are SRNE's Competitive Advantages?
- Proprietary G-MAB antibody library providing a competitive edge in antibody development.
- Innovative drug delivery technologies like Sofusa enhancing treatment efficacy.
- Strong pipeline of diverse therapeutic candidates addressing significant medical needs.
- Strategic collaborations with reputable institutions enhancing research capabilities.
- Experienced management team with a proven track record in biotechnology.
What Does SRNE Do?
Founded in 2006 and headquartered in San Diego, California, Sorrento Therapeutics, Inc. is a clinical-stage and commercial biopharmaceutical company dedicated to developing innovative therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. The company operates through two segments: Sorrento Therapeutics and Scilex. Sorrento Therapeutics leverages its proprietary G-MAB antibody library to develop cancer therapeutics, employing advanced modalities such as chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody-drug conjugates. Additionally, the company has developed Sofusa, a unique drug delivery technology that enables biologics to be delivered directly into the lymphatic system, enhancing therapeutic efficacy. Sorrento's clinical pipeline includes several promising programs, such as anti-CD38 CAR-T therapy for multiple myeloma and resiniferatoxin, a non-opioid neurotoxin for late-stage cancer and osteoarthritis pain. The company also focuses on innovative treatments like ZTlido for postherpetic neuralgia and SEMDEXA, an injectable gel formulation for sciatica, currently in Phase III trials. Sorrento has established collaborations with notable institutions, including SmartPharm Therapeutics for COVID-19 vaccine development and Mayo Clinic for innovative drug delivery studies. With a dedicated workforce of 949 employees, Sorrento is positioned to make significant contributions to the biopharmaceutical landscape.
What Products and Services Does SRNE Offer?
- Develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases.
- Utilizes a proprietary G-MAB antibody library for targeted cancer therapeutics.
- Implements advanced drug delivery technologies, including CAR-T and antibody-drug conjugates.
- Conducts clinical trials for innovative treatments like resiniferatoxin and SEMDEXA.
- Collaborates with leading institutions for research and development of new therapies.
- Focuses on addressing unmet medical needs in various therapeutic areas.
How Does SRNE Make Money?
- Generates revenue through the development and commercialization of biopharmaceutical products.
- Engages in partnerships and collaborations to enhance research capabilities and market reach.
- Invests in clinical trials to advance product candidates toward regulatory approval.
- Explores licensing agreements for proprietary technologies and therapies.
- Utilizes a diverse pipeline to mitigate risks associated with individual product performance.
What Industry Does SRNE Operate In?
The biotechnology industry is experiencing robust growth, driven by advancements in genomics, personalized medicine, and innovative drug delivery systems. Sorrento Therapeutics operates in a competitive landscape, facing peers such as Amgen and Gilead Sciences, but differentiates itself through its proprietary technologies and diverse therapeutic pipeline. The industry's focus on precision medicine and novel therapies positions Sorrento to capitalize on emerging trends and market needs.
Who Are SRNE's Key Customers?
- Healthcare providers seeking innovative treatment options for patients.
- Pharmaceutical companies interested in collaborations and licensing agreements.
- Research institutions involved in clinical trials and therapeutic development.
- Patients suffering from chronic and serious medical conditions.
- Investors looking for opportunities in the biotechnology sector.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Sorrento Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Henry H. Ji. SRNE has traded publicly since 2007.
Financial Health
Sorrento Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -10.88 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
Sorrento Therapeutics, Inc. has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 46.4% below estimates on average.
Forward Outlook
Wall Street analysts project Sorrento Therapeutics, Inc. revenue of about $591.4M for fiscal 2026, with EPS near $0.44.
Insider Activity
12 transactions · 4 purchases, 0 sales, 8 other transactions · 1 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
SRNE Financials
SRNE Latest News
-
Stocks That Hit 52-Week Lows On Monday
benzinga · Dec 19, 2022
SRNE Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for SRNE.
Price Targets
Wall Street price target analysis for SRNE.
SRNE MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for SRNE; grades run from A+ (80-100) to F (below 30).
Leadership: Henry H. Ji
CEO
Henry H. Ji has extensive experience in the biotechnology sector, having co-founded Sorrento Therapeutics in 2006. He holds a Ph.D. in Molecular Biology from the University of California, San Diego, and has held various leadership roles in biopharmaceutical companies, focusing on drug development and commercialization.
Track Record: Under Henry H. Ji's leadership, Sorrento has advanced its therapeutic pipeline significantly, securing collaborations with major research institutions and achieving milestones in clinical development. His strategic vision has positioned the company for future growth in the competitive biotechnology landscape.
SRNE OTC Market Information
The OTC Other tier includes companies that do not meet the requirements for higher tiers like OTCQX or OTCQB, often resulting in less stringent reporting standards. This tier is typically associated with lower liquidity and transparency compared to NYSE or NASDAQ listings.
- OTC Tier: OTC Other
- Limited financial disclosure compared to companies listed on major exchanges.
- Potential for higher volatility and lower liquidity in trading.
- Regulatory risks associated with the biopharmaceutical industry.
- Verify the company's clinical trial progress and results.
- Review financial statements and funding sources.
- Assess the management team's track record and experience.
- Investigate partnerships and collaborations for strategic value.
- Monitor industry trends and competitive landscape.
- Established collaborations with reputable institutions like Mayo Clinic.
- Presence of proprietary technologies with potential market applications.
- A dedicated workforce focused on innovative therapeutic development.
Common Questions About SRNE (Healthcare)
What does Sorrento Therapeutics, Inc. do?
Sorrento Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Financial data is based on the latest available reports.
- Some risks and opportunities are subject to change based on market conditions.